Andrew Matthew Farland, MD
- Clinical Assistant Professor, Hematology and Oncology

Andrew Matthew Farland, MD
- Education
- BS, Virginia Commonwealth University, 2002
- MD, Virginia Commonwealth University, 2006
- Residency
- Internal Medicine, Wake Forest Baptist Medical Center, 2009
- Fellowship
- Hematology / Oncology, Wake Forest Baptist Medical Center, 2012
- Board Certifications
- American Board of Internal Medicine, Hematology
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Medical Oncology
- Positions
- Clinical Assistant Professor, Hematology and Oncology
- Departments and Affiliations
- Hematology and Oncology
Research
- Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration of Alemtuzumab: A Case Report. Liou AA, Skiver BM, Yates E, Persad P, Meyer D, Farland AM, Rocco MV. Am. J. Kidney Dis. 2019 05; 73(5):615-619.
- Correlating S100B with disease course in a case of new onset, acquired thrombotic thrombocytopenic purpura (TTP): Could this be a new predictive biomarker in TTP?. Kuhlman P, Miller P, Farland A, Owen J, Batt K. J Clin Apher. 2018 Aug; 33(4):541-545.
- Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange. Miller PJ, Farland AM, Knovich MA, Batt KM, Owen J. Am. J. Hematol. 2014 Jul; 89(7):695-7.
- Long-term management of acquired thrombotic thrombocytopenic purpura using serial plasma ADAMTS13 measurements. Knovich MA, Farland A, Owen J. Eur. J. Haematol. 2012 Jun; 88(6):518-25.